

TACONIC
Models For Life.

B2m-NOG

A super immunodeficient next generation NOG model with delayed development of Graft vs. Host Disease after human PBMC engraftment, offering a longer study window for immuno-oncology experiments.

ACCESS

- Available for use by commercial customers, including CROs, under simple terms (no MTA, no license fee)

APPLICATION EXPERTISE

- PhD field application scientists provide expertise on experimental design and selection of ideal models

UTILITY FOR IMMUNO-ONCOLOGY STUDIES

B2m-NOG mice offer GvHD-free survival of 8+ weeks after engraftment of human PBMCs. This expands the study window for immuno-oncology efficacy studies using human PBMCs and tumors compared to NOG mice which develop GvHD within 4-6 weeks.

- GvHD onset in all models is influenced by cell dose, irradiation and donor characteristics
- Note that B2m-NOG has reduced efficiency of human PBMC engraftment relative to NOG, as well as a CD4+ bias in peripheral T cells which increases over time

ORDERING INFORMATION

Model #	Description
14957	B2m-NOG
huPBMC-14957	B2m-NOG engrafted with human PBMCs. Produced upon order and delivered within one week of injections.

Get in touch for more information about our products and services.
US: 1-888-822-6642 | **EU:** +45 70 23 04 05 | **info@taconic.com** | Learn more at: **taconic.com/B2m-NOG**

THE COMPLETE SOLUTION

MODELS TO DRIVE DRUG DISCOVERY
Taconic Biosciences is uniquely positioned to enable drug discovery through animal models by being the only company that partners with customers to provide expertise, quality, and availability, along with downstream services:

- Expertise at every step
- Highest quality standards in the industry
- Availability and access to drive global research

MODEL GENERATION SOLUTIONS
Taconic's Model Generation Solutions empower our customers with a unique combination of capabilities, specifically tailored to each individual discovery program:

- Most experienced model generation and breeding company
- Most comprehensive toolkit
- Exclusive programs
- Concierge approach to partnering with customers

COLONY MANAGEMENT SOLUTIONS
Taconic's fully-integrated colony management solutions bring innovative models from design to study-ready cohorts with unprecedented speed and transparency:

- Most experienced model generation and colony management company
- The complete toolkit
- Colony management solution process
- Partnering with our customers
- Expanded applications and opportunities

YOUR PARTNER

WHAT WE DO
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide.

WHO WE ARE
Taconic has created a unique ecosystem of experts to provide our customers with the best animal model solutions. Whether it is choosing the right model for your study, designing a custom model, creating an efficient breeding plan, or providing expertise in critical support functions like veterinary science, genetics, and embryology; Taconic is ready to help you drive your research from idea to cure.

CONTACT US
To get started, contact one of our customer service team members. Contact us at **info@taconic.com**.

VISIT TACONIC.COM
There is so much more to learn. Visit taconic.com. to see our full breadth of animal model solutions and valuable resources.

B2m-NOG has Extended Survival Compared to NOG Following Human PBMC Engraftment



PBMC Engraftment Kinetics



Graphs adapted from Verma et al. 2019

NOG and B2m-NOG mice engrafted via IV tail vein injection using 1 x 10^7 human PBMCs from a single donor

View more data on engraftment kinetics and T cells subsets at **taconic.com/B2m-NOG-poster**

Reference: Verma, B.; Ruggeri, B.; Dubé, P.; Volden, P.; Wesa, A. Unique Immunodeficient Murine Host Strains Impact Expansion and Engraftment of T cells in PBMC Humanized Mice. New York Academy of Sciences' Frontiers in Cancer Immunotherapy. May 14-15, 2019; New York, NY